Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NanosonicsNNCSF +4.66%86 Operating Cash Flow per Share is $0.05 as of Jun. 2026. GuruFocus rates NNCSF with a GF Score™ of 86/100 and a GF Value™ of $3.18 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 653 Medical Devices & Instruments companies, Nanosonics ranks worse than 69.37% on this metric.
Nanosonics's operating cash flow per share for the
six
months ended in Jun. 2026 was $0.04.
Nanosonics's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.05.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Nanosonics was -48.60% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -1.30% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 37.40% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 17.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Nanosonics's Operating Cash Flow per Share or its related term are showing as below:
NNCSF'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -7.2 Med: 12.25 Max: 86.2
Current: -1.3
During the past 13 years, Nanosonics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 86.20% per year. The lowest was -7.20% per year. And the median was 12.25% per year.
NNCSF's 3-Year OCF Growth Rate is ranked worse than 69.37% of 653
companies
in the Medical Devices & Instruments industry
Industry Median: 12.8
vs NNCSF: -1.30
Nanosonics Operating Cash Flow per Share Related Terms
Nanosonics Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Nanosonics's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NNCSF vs ISRG, BDX, RMD: Operating Cash Flow per Share Comparison
For the Medical Instruments & Supplies subindustry, Nanosonics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanosonics Price-to-Operating-Cash-Flow vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nanosonics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Nanosonics's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.05
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of $0.05 mean?
Nanosonics (NNCSF) has a Operating Cash Flow per Share of $0.05 as of Jun. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Nanosonics and its competitors. According to the industry distribution chart, Nanosonics ranks #453 out of 653 companies in the Medical Devices & Instruments industry, placing it in the top 69.4%.
Is Nanosonics' Operating Cash Flow per Share too high?
Nanosonics' current Operating Cash Flow per Share is $0.05. The Medical Devices & Instruments industry median Operating Cash Flow per Share is 12.80. Nanosonics' value of $0.05 is 99.6% below this industry median. Based on the distribution chart, Nanosonics ranks #453 out of 653 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Nanosonics has a GF Score™ of 86/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nanosonics' Operating Cash Flow per Share compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nanosonics ranks #453 out of 653 companies for Operating Cash Flow per Share. This places Nanosonics in the lower half of its industry. The industry median Operating Cash Flow per Share is 12.80. Nanosonics' value of $0.05 is 99.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Medical Devices & Instruments company?
The median Operating Cash Flow per Share among Medical Devices & Instruments companies is 12.80, based on 653 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanosonics's current Operating Cash Flow per Share of $0.05 is 99.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Nanosonics and its competitors. For the Medical Devices & Instruments industry, the median Operating Cash Flow per Share is 12.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanosonics's current Operating Cash Flow per Share is $0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanosonics stock overvalued right now?
Based on GuruFocus' analysis, Nanosonics (NNCSF) is currently considered Possible Value Trap. The stock's GF Value™ is $3.18, compared to a current price of $2.02 — trading 36.5% below its estimated fair value. The current Operating Cash Flow per Share is $0.05 and 99.6% below the Medical Devices & Instruments industry median of 12.80. Nanosonics' overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Nanosonics (NNCSF), the current Operating Cash Flow per Share is $0.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanosonics (NNCSF) Overvalued in 2026?
Based on GuruFocus' analysis, Nanosonics stock appears to be undervalued.
The current stock price of $2.02 is trading 36.5% below its estimated GF Value™ of $3.18.
GuruFocus considers Nanosonics to be Possible Value Trap.
Key valuation signals for NNCSF:
Operating Cash Flow per Share: $0.05
GF Value™: $3.18 vs. price of $2.02 (36.5% below fair value)
Industry Position: 99.6% below the Medical Devices & Instruments median (#453 of 653)
No single metric tells the full story. See the NNCSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanosonics is largely a single-product firm, and its Trophon device provides high-level disinfection of ultrasound probes used in semicritical procedures. The patented technology uses low-temperature sonically activated hydrogen peroxide mist suitable for probes sensitive to damage. Automated HLD is increasingly being used as the standard of care globally as it is superior in preventing cross-infection of patients. Nanosonics' revenue consists of capital sales of Trophon units, ongoing consumables sales, and service revenue. By December 2025, there were 38,000 Trophon units installed globally. Market penetration rates range from over 75% in Australia and New Zealand, over 50% in the US to single-digit penetration in Europe, Middle East, and Africa, and elsewhere in the Asia-Pacific region.
86GF Score
Get the complete analysis for NNCSF
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNCSF has been successfully added to your 
